Medpace (NASDAQ:MEDP) General Counsel Sells $7,357,050.00 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) General Counsel Stephen Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Medpace Trading Up 1.0%

Shares of Medpace stock traded up $4.36 during trading on Monday, reaching $451.47. The company’s stock had a trading volume of 251,185 shares, compared to its average volume of 367,563. The company has a 50-day moving average price of $457.47 and a two-hundred day moving average price of $513.36. Medpace Holdings, Inc. has a fifty-two week low of $291.28 and a fifty-two week high of $628.92. The firm has a market cap of $12.89 billion, a PE ratio of 28.38, a P/E/G ratio of 2.27 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter in the prior year, the business earned $3.67 EPS. Medpace’s quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MEDP has been the topic of a number of research reports. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Mizuho set a $582.00 price objective on Medpace in a research note on Wednesday, February 11th. BMO Capital Markets decreased their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Finally, Robert W. Baird dropped their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $467.08.

Hedge Funds Weigh In On Medpace

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Optiver Holding B.V. purchased a new position in shares of Medpace during the 3rd quarter worth approximately $27,000. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medpace in the fourth quarter valued at approximately $30,000. Elyxium Wealth LLC purchased a new stake in shares of Medpace in the fourth quarter valued at approximately $30,000. Quarry LP acquired a new position in Medpace during the third quarter worth $35,000. Finally, Bayban purchased a new position in Medpace in the fourth quarter worth $44,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.